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Resistance to several prevalent infectious diseases requires both cellular and humoral 
immune responses. T cell immunity is initiated by mature dendritic cells (DCs) in lymphoid 
organs, whereas humoral responses to most antigens require further collaboration between 
primed, antigen-specifi  c helper T cells and naive or memory B cells. To determine whether 
antigens delivered to DCs in lymphoid organs induce T cell help for antibody responses, we 
targeted a carrier protein, ovalbumin (OVA), to DCs in the presence of a maturation stimu-
lus and assayed for antibodies to a hapten, (4-hydroxy-3-nitrophenyl) acetyl (NP), after 
boosting with OVA-NP. A single DC-targeted immunization elicited long-lived T cell helper 
responses to the carrier protein, leading to large numbers of antibody-secreting cells and 
high titers of high-affi  nity antihapten immunoglobulin Gs. Small doses of DC-targeted OVA 
induced higher titers and a broader spectrum of anti-NP antibody isotypes than large doses 
of OVA in alum adjuvant. Similar results were obtained when the circumsporozoite protein 
of Plasmodium yoelii was delivered to DCs. We conclude that antigen targeting to DCs 
combined with a maturation stimulus produces broad-based and long-lived T cell help for 
humoral immune responses.
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DCs are specialized antigen-presenting cells 
that are abundant in lymphoid organs and mu-
cosal surfaces (for review see references 1–4). 
When mature DCs were fi  rst compared with 
other cell types as antigen-presenting cells, they 
were found to be orders of magnitude more 
eff  ective in inducing proliferative, cytotoxic, 
or helper T cell responses in vitro (5–8). Fur-
thermore, small numbers of mature DCs loaded 
with tumor or pathogen-specifi  c antigens in-
duced protective T cell responses when rein-
fused into mice or humans (for review see 
references 9 and 10).
In contrast, when antigens were specifi  cally 
targeted to immature DCs in vivo, antigen pre-
sentation to CD4+ and CD8+ T cells led to 
profound peripheral T cell tolerance by dele-
tion, anergy, or induction of regulatory T cells 
(11–14). The same antigens delivered to DCs in 
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conjunction with a stimulus for their diff  erenti-
ation or maturation, such as anti-CD40  antibody 
(15), elicited strong T cell immune responses 
(11, 16). We have proposed that this dual func-
tion of DCs in tolerance and immunity may be 
required to prevent anti–self-immune responses. 
By continually picking up, processing, and pre-
senting antigen in the steady-state, DCs may 
avert anti–self-responses when a combination 
of self- and foreign antigens are presented to 
T cells during infection (17).
In the course of developing a method for 
antigen delivery to DCs in vivo, we found 
that proteins delivered to DCs by antibodies 
to the DEC-205 receptor were at least two 
orders of magnitude more eff  ective  than 
  nontargeted antigens in activating T cell pro-
liferation,   production of IFN-γ, and protec-
tion against vaccinia virus infection (11, 12, 
16). Thus,   specifi  c antigen delivery to DCs in 
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be an   eff  ective method to produce protein vaccines that 
  induce strong   cellular immunity (16, 18). However, cellular 
immunity is not suffi   cient for protection against many path-
ogens, and in these instances, humoral immunity is required 
for   optimal vaccination.
Here, we report on T cell–dependent antibody responses 
elicited by antigens targeted to DCs in vivo.
RESULTS
Production of fusion mAbs with full-length OVA
Immunization with protein antigens in adjuvant elicits T cell 
help for antibody formation. The most direct and general 
method to assess this type of T cell help is to measure anti-
body responses to haptens coupled to carrier proteins. In this 
assay, mice primed with the carrier protein are challenged 
with a conjugate of the same protein with a hapten (19–22). 
The antihapten antibody responses are dependent on contact 
between naive hapten-specifi   c B cells and anti-  carrier–
specifi  c memory T helper cells elicited during the initial 
  immunization (20).
To determine whether antigens targeted to DCs in vivo 
produce T cell help for antibody responses, we used OVA 
as the carrier protein and (4-hydroxy-3-nitrophenyl) acetyl 
(NP) as the hapten. The carrier was delivered to DCs by 
cloning OVA in frame with the carboxyl terminus of the 
heavy chain of the αDEC-205 (anti–DEC-OVA) antibody 
that targets DCs in vivo (11). Constant regions of the original 
rat αDEC and isotype control antibody (control-OVA) were 
replaced by that of the mouse IgG1 and modifi  ed to avoid 
Fc-receptor binding (11). The fusion mAbs were produced 
by transient transfection and binding to DEC-205 was con-
fi  rmed by fl  ow cytometry (Fig. S1, A and B, available at 
http://www.jem.org/cgi/content/full/jem.20051639/DC1).
Strong T cell responses to a single dose of anti–DEC-OVA 
plus maturation stimulus
Naive C57BL/6 mice were immunized with 10 μg anti– 
DEC-OVA or control-OVA (corresponding to  3.5 μg 
OVA) in the presence or absence of a DC maturation stimu-
lus (anti-CD40 plus poly I:C) or with 100 μg of alum-pre-
cipitated LPS-free OVA (alum plus OVA) because the latter 
is considered to be eff  ective in producing T cell help for 
antibody responses. 14 d later, T cells isolated from immu-
nized mice were pulsed with peptide pools from a library of 
overlapping OVA 12–17-mer peptides (Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20051639/
DC1), and IFN-γ secretion was measured by fl  ow cytom-
etry. We detected IFN-γ secretion by CD4+ and CD8+ 
T cells in response to OVA peptides in the group immunized 
with anti–DEC-OVA plus maturation stimulus, but not in 
any of the other groups, including mice primed with alum 
plus OVA (Fig. 1, boxed plot). When we broke down the 
pools into individual peptides, the CD8+ T cells recognized 
peptides containing the known H-2Kb binding sequence 
SIINFEKL and two other mimetope peptides, whereas the 
CD4+ T cell response was restricted to a previously unde-
fi  ned helper peptide, E  K  L  T  E  W  T  S  S  N  V  M  E  E  R   (Fig. S1 C). 
We conclude that immunization with  3.5  μg OVA in 
the form of anti–DEC-OVA fusion protein induces CD4+ 
and CD8+ T cell responses, whereas the immunization with 
alum-precipitated OVA does not.
Broad and long-lived humoral immune responses 
with DC-targeted T cell help
To examine humoral immune responses, C57BL/6 mice 
were primed with 3 μg of the fusion antibodies ( correspond-
ing to  1.0 μg OVA) and boosted with 1 μg OVA-NP11 
Figure 1.  Immunization with anti–DEC-OVA fusion mAb primes 
OVA-specifi  c T cells. IFN-γ production by CD4+ and CD8+ T cells is 
shown as dot plots of gated CD3+ T cells stained for CD4 and intracellular 
IFN-γ. Immunization conditions are displayed on the right, and the 
peptide pool numbers are shown on top. Numbers represent the percent 
of IFN-γ+ CD3+ CD4− (left panels) or IFN-γ+ CD3+ CD4+ (right panels) 
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in PBS 4 wk after the primary immunization. Mice were 
bled before and 7 and 14 d after the boost, and IgG anti-
body responses were measured by ELISA using NP2-BSA 
for antibody capture because high-affi   nity antibodies bind 
to proteins derivatized with small numbers of NP groups, 
whereas low-affi   nity antibodies do not (23). High titers of 
high-affi   nity anti-NP antibodies were found in mice primed 
with anti–DEC-OVA plus maturation stimulus, but not with
anti–DEC-OVA or maturation stimulus alone (Fig. 2 A).
Immunization with 100 μg of alum-precipitated OVA 
Figure 2.  Immunization with anti–DEC-OVA fusion mAb primes 
helper T cells for antibody responses. (A) Anti-NP IgG antibody titers 
before and 7 or 14 d after an i.p. boost injection with 1 μg OVA-NP11 in 
PBS. Immunization conditions are displayed at the top. Symbols repre-
sent individual mice, and the curves represent the mean value of each 
group. (B) Antibody-secreting cells in the spleen or bone marrow mea-
sured by ELISPOT on NP2-BSA 14 d after an i.p. boost with 1 μg OVA-NP11 
in PBS. Symbols indicate individual mice. Initial immunization conditions 
were as follows: PBS (■), anti–DEC-OVA (▲), anti–DEC-OVA plus anti-
CD40 plus poly I:C (▼), control-OVA plus anti-CD40 plus poly I:C (◆), 
anti-CD40 plus poly I:C (●), and alum plus OVA (×). (C) Anti-NP anti-
body titers for individual IgG isotypes and IgM 14 d after an i.p. boost 
with 1 μg OVA-NP11 in PBS. The horizontal lines represent the mean 
value of each group. Symbols indicate individual mice and initial immu-
nization conditions as described in B. (D) Anti-NP IgG antibody responses 
measured by ELISA in mice immunized with anti–DEC-OVA plus anti-
CD40 plus poly I:C 4, 6, 8, or 12 wk before i.p. boosting with 1 μg 
OVA-NP11 in PBS. Antibody titers were measured as described in A. 
(E) Anti-OVA IgG antibody titers in mice immunized with anti–DEC-OVA 
plus anti-CD40 plus poly I:C and then boosted 6 wk later with 1 μg 
of either OVA, anti–DEC-OVA, or control-OVA. Antibody titers were 
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(LPS-free) or control-OVA plus maturation stimulus was one 
and two orders of magnitude less eff  ective, respectively, than 
immunization with anti–DEC-OVA and maturation stimulus 
(Fig. 2 A). The number of IgG-producing cells in the spleen 
and bone marrow was measured by ELISPOT. We found 
NP-specifi  c antibody-producing cells in the spleen and bone 
marrow (Fig. 2 B) of mice immunized with anti–DEC-OVA 
plus maturation stimulus and with alum plus OVA. Collec-
tively, these results lead us to conclude that immunization by 
antigen targeting to DCs is eff  ective in eliciting T cell help 
for humoral responses.
To further characterize the antibody response, we deter-
mined the subclass specifi  city of the anti-NP Ig response. Im-
munization with anti–DEC-OVA plus maturation stimulus 
elicited eff  ective T cell help for B cells and antibodies of all 
IgG subclasses as well as IgM (Fig. 2 C). In contrast, NP re-
sponses in mice primed with alum plus OVA were mainly 
restricted to the IgG1 subclass (Fig. 2 C). As an additional 
control, we immunized groups of mice with anti–DEC-
OVA plus poly I:C. The administration of poly I:C in con-
junction with anti–DEC-OVA elicited very low antibody 
responses (unpublished data). We conclude that immuniza-
tion by DC targeting produces T cell help that induces a 
broad spectrum of antibody isotypes.
To determine whether antigen targeting to DCs leads to 
long-lasting helper T cell responses, we primed mice with 
anti–DEC-OVA plus maturation stimulus and boosted them 
with 1 μg OVA-NP11 4, 6, 8, or 12 wk after primary immu-
nization. High titers of anti-NP antibodies were elicited by 
the boost 12 wk after the primary immunization, the longest 
point we tested, indicating the persistence of helper T cells 
long after a single immunization with anti–DEC-OVA plus 
maturation stimulus (Fig. 2 D). Thus, antigen targeting to 
DCs leads to effi   cient long-lived helper T cell responses for 
antibody formation.
To determine whether anti–DEC-OVA would be an ef-
fective secondary immunogen we compared it with OVA. 
Mice primed with anti–DEC-OVA plus maturation stimulus 
were boosted with 1 μg OVA, anti–DEC-OVA, or control-
OVA in PBS, and anti-OVA responses were measured by 
ELISA (Fig. 2 E). We found no diff  erence in the antibody 
  titers among the various groups, suggesting that boosting with 
anti–DEC-OVA fusion antibody is eff  ective in eliciting 
T-dependent antibody responses.
T cell responses to a malaria protein after 
DEC-205–mediated delivery
To determine whether antigen targeting to DCs by αDEC-
205 elicits antibodies to potential vaccine target antigens, we 
measured immune responses to the circumsporozoite protein 
(CSP) of Plasmodium yoelii, which causes murine malaria. We 
chose CSP because it is the major immunogen on the surface 
of malaria sporozoites, and it has demonstrated effi   cacy in 
murine and human vaccine trials (24–27).
αDEC-CS and control-CS fusion antibodies were pro-
duced and tested for binding to DEC-205 as described for 
anti–DEC-OVA above (Fig. S2, A and B, available at http://
www.jem.org/cgi/content/full/jem.20051639/DC1). In 
addition, we verifi  ed antigen processing and presentation in 
vivo using transgenic CD8+ T cells specifi  c for the previously 
characterized CSP CD8 epitope (SYVPSAEQI; reference 28). 
Anti-CSP transgenic CD8+ T cells transferred into BALB/c 
mice proliferated extensively in response to immunization 
with 2 μg αDEC-CS (corresponding to  0.7 μg CSP) and 
only minimally to control-CS antibody, suggesting that DCs 
targeted with αDEC-CS effi     ciently process and present 
CSP to CD8+ T cells in vivo (Fig. S2 C).
To assess the effi   cacy of T cell immunization by αDEC-
CS plus a maturation stimulus, we compared it with irra-
diated sporozoites in diff  erent strains of naive mice. Mice 
were immunized i.p. with a single dose of αDEC-CS plus 
maturation stimulus or i.v. with a single dose of 7.5 × 104 
irradiated sporozoites. CD4+ T cell responses were assayed 
by ELISPOT by measuring IFN-γ secretion in response to 
pools of overlapping CSP 12–16-mer peptides comprising 
the N- and COOH-terminal domains of CSP (Fig. 3 A and 
Table S2, available at http://www.jem.org/cgi/  content/full/
jem.20051639/DC1). One injection of αDEC-CS plus a 
Figure 3.  Immunization with 𝗂DEC-CS primes helper and CD8+ 
T cells. (A) IFN-γ production by CD4+ (A) and CD8+ (B) T cells measured 
by ELISPOT assay 14 d after immunization. Plots show numbers of spots 
per 106 T cells from mice immunized i.p. with 10 μg αDEC-CS plus 
anti-CD40 plus poly I:C (black bars) or PBS (striped bars), or anti-CD40 
plus poly I:C (gray bars) or i.v. with 7.5 × 104 irradiated sporozoites 
(white bars). Mouse strains are indicated at the top.JEM VOL. 203, March 20, 2006  603
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maturation stimulus elicited strong CD4+ T cell responses 
to at least two separate epitopes in naive BALB/c, C57BL/6, 
and B10.BR mice (i.e., three diff   erent MHC haplotypes: 
H-2d, H-2b, and H-2k), but irradiated sporozoites and other 
controls did not (Fig. 3 A). In BALB/c mice, the response 
was directed against the previously described peptides K  I  Y-
N  R  N  I  V  N  R  L  L  G  D  A   (29) and S  Q  L  T  E  E  W  S  Q  C  S  V  T  C  G   
(30), whereas in C57BL/6 mice, CD4+ T cells recognized 
peptides K  I  Y  N  R  N  I  V  N  R  L  L  G  D  A   and A  Q  N  K  L  N  Q  P  V  V  A-
D  E  N  V  . CD8+ T cell responses were measured in BALB/
c mice by assaying IFN-γ secretion in response to a previ-
ously described peptide epitope (SYVPSAEQI; Fig. 3 B; ref-
erence 31). We found that immunization with αDEC-CS 
induced similar numbers of IFN-γ–producing CD8+ T cells 
as generated by irradiated sporozoites (Fig. 3 B). Thus, when 
compared with a single dose of irradiated sporozoites, one in-
jection with αDEC-CS plus maturation stimulus is as eff  ec-
tive in eliciting CSP-specifi  c CD8+ T cells, and even better 
in eliciting CD4+ T cells.
Strong anti-CSP antibody responses after priming 
with DEC-205–targeted CSP
P. yoelii CSP has a central domain composed of two tandem 
repeats corresponding to major and minor immunodominant 
serological epitopes (QGPGAP and QQPP, respectively; 
reference 32). To examine humoral responses against CSP, 
we immunized BALB/c mice with αDEC-CS plus matura-
tion stimulus or with maturation stimulus alone and boosted 
them with αDEC-CS after 8 wk. As a positive control, we 
also immunized mice with a single dose of irradiated sporo-
zoites. Mice were bled before and 7 d after the boosting, and 
the IgG antibody titers were measured by ELISA against the 
major B cell epitope (29) and by indirect immunofl  uores-
cence assay on P. yoelii parasites. We found that mice primed 
with 10 μg αDEC-CS plus maturation stimulus and boosted 
with 10 μg αDEC-CS produced high antibody titers when 
compared with controls (Fig. 4 A and Table I). As shown 
above for anti–DEC-OVA, αDEC-CS immunization elic-
ited antibodies of all IgG isotypes (Fig. 4 B). We conclude 
that immunization by targeting antigens to DCs by DEC-
205 together with a maturation stimulus produces a broad 
spectrum of T cell help for humoral immune responses to 
P. yoelii CSP.
High frequencies of anti-CSP hybridomas after priming 
with DEC-205–targeted CSP
As a measure of the number of activated B cells in mice im-
munized with αDEC-CS, we produced hybridomas after 
immunization and boosting with 10 μg αDEC-CS antibody. 
For comparison, we also generated hybridomas after immu-
nization and boosting with 7.5 × 104 irradiated sporozoites. 
Hybridomas were screened by ELISA for reactivity against 
the major (QGPGAP) or minor (QQPP) immunodominant 
B cell epitopes. We found that 16.4% of all wells screened 
from the αDEC-CS immunization were reactive to the major 
or minor epitopes. In contrast, only 0.8% of all wells screened 
from the irradiated sporozoite immunization were positive, 
and these were all specifi  c for the major immunodominant 
repeat (Table II). Finally, the hybridoma antibody isotypes 
obtained by αDEC-CS immunization were representative 
of the broad range of isotypes found in serum by ELISA 
Figure 4.  Immunization with DEC-CS primes helper cells for an-
tibody responses. (A) Anti-QGPGAP IgG antibody titers before and 7 d 
after an i.p. boost injection with 10 μg αDEC-CS in PBS. Immunization 
conditions are displayed at the top of each panel. Symbols represent 
individual mice, and the curves represent the mean value of each group. 
(B) Anti-QGPGAP antibody titers for individual IgG isotypes and IgM 7 d 
after an i.p. boost with 10 μg αDEC-CS in PBS. The horizontal lines rep-
resent the mean value of each group. Initial immunization conditions 
were as follows: PBS (■), αDEC-CS plus anti-CD40 plus poly I:C (▼), 
and anti-CD40 plus poly I:C (●). As control, one group of mice was 
immunized with 7.5 × 104 irradiated sporozoites (×) and bled 8 wk 
later at the same time as the other groups. Symbols represent 
individual mice.
Table I. Immunofl  uorescence titers in mice immunized 
with αDEC-CS antibody
Primea Boostb Reciprocal IFA titerc
PBS αDEC-CS <600
αDEC-CS+anti-CD40+poly I:C αDEC-CS 106,920 (±53,237)
anti-CD40+poly I:C αDEC-CS 900 (±600)
Irradiated sporozoites — 4,500 (±1,800)
aGroups of four mice were primed with 10 μg αDEC-CS plus maturation stimulus, 
maturation stimulus alone, 7.5 × 104 irradiated sporozoites, or PBS.
bMice were boosted with 10 μg αDEC-CS or nothing.
cImmunofl  uorescence assay was performed 7 d after boost using serial dilutions 
of serum from individual mice. Results are depicted as the mean of reciprocal 
titers ±SD.604  DENDRITIC CELL TARGETING INDUCES ANTIBODY RESPONSES | Boscardin et al.
(Table III). We conclude that immunization with αDEC-
CS in the presence of maturation stimulus produces eff  ective 
T cell help for a broad spectrum of anti-CSP antibodies.
DISCUSSION
T cell–dependent antibody responses are initiated at the in-
terface of the T and B cell follicle where antigen-specifi  c 
T and B cells interact (33, 34). The requirements for this in-
teraction include capture and display of processed antigen by 
the B cell to a helper T cell, costimulation by cell surface 
molecules such as CD40-CD40L, and secretion of cytokines 
by activated T cells (35). The initial T–B cell interaction leads 
to germinal center formation, somatic hypermutation, and 
isotype switching. The isotype of the switched antibodies 
produced in this reaction is determined mainly by the cyto-
kine secreted by the helper T cells. For example, the helper 
type 1 cytokine IFN-γ is associated with production of 
IgG2a, whereas the helper type 2 cytokine IL-4 supports 
switching to IgG1 (for review see reference 36). Therefore, 
the isotypes of the T cell–dependent antibodies produced 
during an   immune response are a refl  ection of T cell polar-
ization.   Immunization by DC targeting induces helper 
T type 1 IFN-γ–producing CD4+ T cells and CD8+ T cells, 
as well as protection against vaccinia infection (16). Our 
  experiments establish that immunization by DC targeting 
also leads to long-lived T cell help for a broad range of diff  er-
ent antibody isotypes and therefore a combination of helper 
T type 1 and 2 responses.
Vaccination against many pathogens, including HIV and 
malaria, requires both cellular and humoral responses. In the 
case of HIV, mAbs to the conserved epitopes on proteins 
gp120 and gp41 (37–39) are suffi   cient for viral neutraliza-
tion, and in malaria, mAbs to CSP are protective in mice and 
monkeys (40–42). However, it has been diffi   cult to obtain 
  eff  ective immunization to protein antigens in humans or mice 
using conventional approaches. We would like to suggest 
that direct antigen targeting to DCs in vivo in combination 
with a maturation stimulus may be a safe and eff  ective means 
to produce long-lived, broad-based cellular and humoral im-
mune responses to specifi  c candidate vaccine proteins.
MATERIALS AND METHODS
Construction and production of the hybrid antibodies. The entire 
cDNA encoding chicken OVA was cloned in frame with the carboxyl ter-
minus of the heavy chain of mouse αDEC-205 or isotype control antibodies 
(11). Likewise, an 870-bp sequence comprising amino acids 57–346 from 
the CSP of P. yoelii (17X NL strain; reference 32) was cloned into the anti-
bodies to produce αDEC-CS or isotype control. Hybrid antibodies were 
produced by transient transfection in 293T cells using calcium phosphate as 
described previously (11), and the fusion antibodies were purifi  ed on Protein 
G columns (GE Healthcare). These were assayed for binding to stable DEC-
205 transfectants, which were provided by C.G. Park (The Rockefeller Uni-
versity, New York, NY).
Mice. 6–8-wk-old adult female BALB/c, B10.BR, and C57BL/6 mice were 
purchased from Taconic Farms or Charles River Laboratories and used accord-
ing to institutional guidelines. SYVPSAEQI-specifi  c T cell receptor transgenic 
mice were described previously (28). Protocols were approved by the Institu-
tional Animal Care and Use Committee at The Rockefeller University.
Peptide libraries. Peptide libraries for OVA and CSP were synthesized in 
collaboration with the Proteomics Resource Center, The Rockefeller Uni-
versity. Details on how the libraries were prepared are available in the online 
supplemental material (see below).
Immunizations. Mice were primed once i.p. with 3 or 10 μg anti–DEC-
OVA (as indicated in Results) or 10 μg αDEC-CS in the presence of 50 μg 
anti-CD40 antibody (clone 1C10) and 50 μg poly I:C (Invivogen) or the 
same doses of αCD40 and poly I:C alone or with 100 μg of LPS-free OVA 
(Seikagaku Corp.) precipitated in alum (Pierce Chemical Co.) or 7.5 × 104 
irradiated sporozoites (γ-source, 20 krad). Antibodies were elicited by boost-
ing the mice once i.p. with either 1 μg OVA-NP11, anti–DEC-OVA, con-
trol-OVA, or 10 μg of the αDEC-CS in PBS.
Table II. Number of mAbs generated by immunization with irradiated sporozoites or αDEC-CS plus maturation stimulus
Immunization method Number of screened clonesa Number of positive clones
(% of the total screened)
Positive clones (%)b
Major repeat Minor repeat
Irradiated sporozoitesc 1,277 10 (0.8) 100 0
αDEC-CS+anti-CD40+polyI:Cd 736 121 (16.4) 55.4 44.6
aGrowing clones were screened for antibody secretion.
bGrowing clones were screened for reactivity against sequences representing the major repeat (QGPGAP)2 or the minor repeat (QQPP)2 of CSP.
cPrime and boost were performed i.v. with 7.5 × 10
4 irradiated sporozoites in the interval of a month. The fusion was performed 3 d after the boost dose.
dPrime i.p. with 10 μg αDEC-CS plus anti-CD40 plus poly I:C. 21 wk later, the boost was performed i.p. with 10 μg αDEC-CS. The fusion was performed 3 d after the 
boost dose.
Table III. mAb subclasses generated by the immunization with irradiated sporozoites or with αDEC-CS plus maturation stimulus
Immunization methoda Positive clones against the major repeat (%)b Positive clones against the minor repeat (%)b
IgG1 IgG2a IgG2b IgG3 IgG1 IgG2a IgG2b IgG3
Irradiated sporozoites 70 10 0 20 0 0 0 0
αDEC-CS+anti-CD40+poly I:C 56.7 9 7.5 26.9 25.9 25.9 40.7 7.4
aMice were immunized as described in Table II.
bAll positive clones were rescreened against the major and minor repeats of CSP using anti–mouse subclass-specifi  c secondary antibodies.JEM VOL. 203, March 20, 2006  605
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Intracellular cytokine staining. Intracellular IFN-γ production by primed 
CD4+ and CD8+ T cells was evaluated using bulk splenocytes incubated 
with 2 μM of the OVA peptide pools or medium alone in the presence of 
2 μg/ml of costimulatory αCD28 antibody (clone 37.51). Cells were cul-
tured for 6 h in the presence of brefeldin A (BD Biosciences), incubated with 
αCD16/CD32 antibody to block Fcγ receptors, and stained with anti–
mouse CD4 (clone GK 1.5), CD8 (clone 53-6.7), and CD3 (clone 145-
2C11) antibodies for 15 min at 4°C. After fi  xation with Cytofi  x/Cytoperm 
Plus (BD Biosciences), cells were stained for intracellular IFN-γ (XMG1.2) 
for 15 min at room temperature. All mAbs were purchased from BD Biosci-
ences. Data was collected using FACSCalibur and analyzed using FlowJo 
software (Tree Star).
ELISA and B cell ELISPOT. For the detection of NP- or CSP-specifi  c 
antibodies, high-binding ELISA plates (Costar) were coated overnight with 
5 μg/ml NP2-BSA (Biosearch Technologies) or (QGPGAP)2 peptide in 
PBS. Plates were then washed three times with PBS-Tween 20 0.02% and 
blocked with PBS-BSA 1% for 1 h at room temperature. Serial dilutions of 
the sera in PBS-BSA 0.25% were incubated for 2 h at room temperature and 
visualized with goat anti–mouse IgG Fc-specifi  c antibody conjugated to 
horseradish peroxidase (1:2,000; Jackson ImmunoResearch Laboratories) or 
anti–mouse subclass-specifi  c antibodies (1:500; SouthernBiotech), followed 
by colorimetric assay using 1-Step ABTS. OD405 was measured using a 
VERSAmax microplate reader (Molecular Devices). Titers represent the 
highest dilution of serum showing an OD405 >0.1. The results are presented 
as the log10 antibody titer of each individual mouse. For the anti-NP anti-
body-producing B cell assay, ELISPOT plates (MAIPS; Millipore) were 
coated as described above and blocked with RPMI 5% FBS (Invitrogen) for 
1 h at 37°C and 5% CO2. Serial dilutions of splenocyte suspensions were 
prepared in RPMI 5% and incubated in the coated wells for 6 h at 37°C in 
5% CO2. Anti-NP antibody-secreting cells were visualized by incubation 
with goat anti–mouse IgG Fc-specifi  c antibody conjugated to horseradish 
peroxidase (1:2,000; Jackson ImmunoResearch Laboratories), followed by 
substrate from the AEC kit (Vector Laboratories). Spots were counted in an 
ELISPOT reader (Autoimmun Diagnostika GmbH).
IFN-𝗄 ELISPOT. ELISPOT plates (MAHAS; Millipore) were coated with 
10 μg of the anti–mouse IFN-γ mAb (clone R4-6A2; BD Biosciences) 
overnight at room temperature, and plates were blocked by incubation with 
PBS-BSA 1% for at least 2 h at 37°C. Spleen CD8+ T cells were purifi  ed 
by negative selection using αCD19 and αCD11c antibody beads, followed 
by positive selection on αCD8 beads (Miltenyi Biotec). The fl  ow through 
was CD4+ T cell enriched. Purifi  ed T cells were then cultured for 36–40 h 
at 37°C with 5% CO2 in the presence of 2 μM peptide, and CD11c+ DCs 
purifi  ed by positive selection. Plates were developed with anti–IFN-γ bio-
tinylated antibody (BD Biosciences), and spots visualized with avidin–horse-
radish peroxidase (Vector Laboratories), followed by DAB as substrate 
(Invitrogen). Spots were counted in an ELISPOT reader (Autoimmun 
  Diagnostika GmbH).
mAbs. BALB/c mice were immunized either i.p. with 10 μg αDEC-CS 
plus maturation stimulus or i.v. with 7.5 × 104 irradiated sporozoites. The 
mouse that received the αDEC-CS plus maturation stimulus was boosted 
21 wk later i.p. with 10 μg αDEC-CS. The mouse immunized with ir-
radiated sporozoites was boosted 4 wk later i.v. with another dose of 7.5 × 
104 irradiated sporozoites. 3 d after boost, splenocytes were fused with an 
appropriate myeloma partner in the Monoclonal Antibody Core Facility, 
Memorial Sloan-Kettering Cancer Center. Screening was performed by 
ELISA using the peptides (QGPGAP)2 or (QQPP)2 and the same conditions 
described above.
Online supplemental material. Fig. S1, A and B, shows the purifi  cation 
and binding of the antibodies anti–DEC-OVA and control-OVA to CHO 
cells stably transfected with DEC-205, and C shows IFN-γ CD8+ and 
CD4+ T cell responses for individual peptides contained in pool 8. Fig. S2, 
A and B, shows the purifi  cation and binding of the antibodies αDEC-CS 
and control-CS to CHO cells stably transfected with DEC-205, and C 
shows transgenic CD8+ T cell proliferation in mice injected with αDEC-CS 
or control-CS. Tables S1 and 2 show the peptide libraries generated for 
OVA and CSP, respectively. Details on the peptide libraries generation, 
adoptive transfer, and analysis of TCR transgenic T cell proliferation and 
immunofl  uorescence on P. yoelii sporozoites can be found in supplemental 
Materials and methods. Figs. S1 and S2 and Tables S1–S2 are available at 
http://www.jem.org/cgi/content/full/jem.20051639/DC1.
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